Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

613 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer.
Henick BS, Villarroel-Espindola F, Datar I, Sanmamed MF, Yu J, Desai S, Li A, Aguirre-Ducler A, Syrigos K, Rimm DL, Chen L, Herbst RS, Schalper KA. Henick BS, et al. Among authors: syrigos k. J Immunother Cancer. 2022 Jul;10(7):e005025. doi: 10.1136/jitc-2022-005025. J Immunother Cancer. 2022. PMID: 35793873 Free PMC article.
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Georgoulias V, Kouroussis C, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E, Polyzos A, Syrigos K, Veslemes M, Toubis M, Ardavanis A, Tselepatiotis E, Vlachonikolis I; Lung Cancer Committee of the Hellenic Oncology Research Group. Georgoulias V, et al. Among authors: syrigos k. Br J Cancer. 2004 Aug 2;91(3):482-8. doi: 10.1038/sj.bjc.6602010. Br J Cancer. 2004. PMID: 15238986 Free PMC article. Clinical Trial.
Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.
Georgoulias V, Agelidou A, Syrigos K, Rapti A, Agelidou M, Nikolakopoulos J, Polyzos A, Athanasiadis A, Tselepatiotis E, Androulakis N, Kalbakis K, Samonis G, Mavroudis D. Georgoulias V, et al. Among authors: syrigos k. Br J Cancer. 2005 Oct 3;93(7):763-9. doi: 10.1038/sj.bjc.6602748. Br J Cancer. 2005. PMID: 16175189 Free PMC article. Clinical Trial.
Targeted therapies for non-small cell lung cancer.
Papaetis GS, Roussos C, Syrigos KN. Papaetis GS, et al. Among authors: syrigos kn. Curr Pharm Des. 2007;13(27):2810-31. doi: 10.2174/138161207781757079. Curr Pharm Des. 2007. PMID: 17897025 Review.
Analytic variability in immunohistochemistry biomarker studies.
Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL. Anagnostou VK, et al. Among authors: syrigos kn. Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):982-91. doi: 10.1158/1055-9965.EPI-10-0097. Epub 2010 Mar 23. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20332259 Free PMC article.
613 results